Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048817 | 0.90 | PRMT6 (0.60) | PRMT6PSMB5TAAR1KEAP1KDM4E | |
| SCHEMBL14141440 | 0.86 | PRMT6 (0.68) | PRMT6PSMB5TAAR1KEAP1KDM4E | |
| SCHEMBL1347949 | 0.83 | PRMT6 (0.59) | PRMT6PSMB5TAAR1KEAP1KDM4E | |
| SCHEMBL1346211 | 0.83 | PRMT6 (0.59) | PRMT6PSMB5TAAR1KEAP1KDM4E | |
| SCHEMBL12133815 | 0.82 | PRMT6 (0.59) | PRMT6PSMB5TAAR1KEAP1 | |
| SCHEMBL10190883 | 0.81 | PRMT6 (0.62) | PRMT6PSMB5TAAR1KEAP1KDM4E | |
| SCHEMBL10243010 | 0.81 | PRMT6 (0.54) | PRMT6PSMB5TAAR1KEAP1KDM4E | |
| SCHEMBL10242910 | 0.80 | PRMT6 (0.53) | PRMT6PSMB5TAAR1KEAP1CTSS | |
| SCHEMBL30777855 | 0.79 | CTSS (0.51) | PRMT6CTSSCTSK | |
| SCHEMBL196298 | 0.79 | CTSS (0.51) | PRMT6CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | PRMT6 710/4885PSMB5 2112/4885TAAR1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.